UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549

 

SCHEDULE 13D

 

Under the Securities Exchange Act of 1934

 

(Amendment No.  )*

 

GENMARK DIAGNOSTICS, INC.

(Name of Issuer)

 

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

 

372309104

(CUSIP Number of Class of Securities)

 

Alec N. Litowitz

Magnetar Capital LLC

1603 Orrington Ave.

Evanston, Illinois 60201

(847) 905-4400

(Name, Address and Telephone Number of Person Authorized
to Receive Notices and Communications)

 

March 19, 2021

(Date of Event which Requires Filing of this Statement)

 

If the filing person has previously filed a Statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D and is filing this Schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box. ¨

 

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 240.13d-7(b) for other parties to whom copies are to be sent.

 

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

 

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

 

 

CUSIP No. 372309104 SCHEDULE 13D Page 2 of 10

 

1. NAME OF REPORTING PERSON:
   
  Magnetar Financial LLC
 
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
  (a)        ¨
  (b)       x
 
3. SEC USE ONLY
 
4. SOURCE OF FUNDS
 
  OO
   
5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) ¨
   
   
6. CITIZENSHIP OR PLACE OF ORGANIZATION
   
  Delaware

NUMBER OF

 SHARES

BENEFICIALLY

OWNED BY

EACH REPORTING

PERSON

WITH

  7. SOLE VOTING POWER
     
    0
  8. SHARED VOTING POWER
     
    4,221,792
  9. SOLE DISPOSITIVE POWER
     
    0
  10. SHARED DISPOSITIVE POWER
     
    4,221,792

11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
   
  4,221,792
12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
   
13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
   
  5.74%
14. TYPE OF REPORTING PERSON
   
  IA; OO
   

 

 

 

 

CUSIP No. 372309104 SCHEDULE 13D Page 3 of 10

 

1. NAME OF REPORTING PERSON:
   
  Magnetar Capital Partners LP
 
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
  (a)        ¨
  (b)       x
 
3. SEC USE ONLY
 
4. SOURCE OF FUNDS
 
  OO
   
5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) ¨
   
   
6. CITIZENSHIP OR PLACE OF ORGANIZATION
   
  Delaware

NUMBER OF

 SHARES

BENEFICIALLY

OWNED BY

EACH REPORTING

PERSON

WITH

  7. SOLE VOTING POWER
     
    0
  8. SHARED VOTING POWER
     
    4,221,792
  9. SOLE DISPOSITIVE POWER
     
    0
  10. SHARED DISPOSITIVE POWER
     
    4,221,792

11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
   
  4,221,792
12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
  ¨
13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
   
  5.74%
14. TYPE OF REPORTING PERSON
   
  HC; OO
   

 

 

 

 

CUSIP No. 372309104 SCHEDULE 13D Page 4 of 10

 

1. NAME OF REPORTING PERSON:
   
  Supernova Management LLC
 
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
  (a)        ¨
  (b)       x
 
3. SEC USE ONLY
 
4. SOURCE OF FUNDS
 
  OO
   
5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) ¨
   
   
6. CITIZENSHIP OR PLACE OF ORGANIZATION
   
  Delaware

NUMBER OF

 SHARES

BENEFICIALLY

OWNED BY

EACH REPORTING

PERSON

WITH

  7. SOLE VOTING POWER
     
    0
  8. SHARED VOTING POWER
     
    4,221,792
  9. SOLE DISPOSITIVE POWER
     
    0
  10. SHARED DISPOSITIVE POWER
     
    4,221,792

11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
   
  4,221,792
12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
  ¨
13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
   
  5.74%
14. TYPE OF REPORTING PERSON
   
  HC; OO
   

 

 

 

 

CUSIP No. 372309104 SCHEDULE 13D Page 5 of 10

 

1. NAME OF REPORTING PERSON:
   
  Alec N. Litowitz
 
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
  (a)        ¨
  (b)       x
 
3. SEC USE ONLY
 
4. SOURCE OF FUNDS
 
  OO
   
5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) ¨
   
   
6. CITIZENSHIP OR PLACE OF ORGANIZATION
   
  United States of America

NUMBER OF

 SHARES

BENEFICIALLY

OWNED BY

EACH REPORTING

PERSON

WITH

  7. SOLE VOTING POWER
     
    0
  8. SHARED VOTING POWER
     
    4,221,792
  9. SOLE DISPOSITIVE POWER
     
    0
  10. SHARED DISPOSITIVE POWER
     
    4,221,792

11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
   
  4,221,792
12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
  ¨
13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
   
  5.74%
14. TYPE OF REPORTING PERSON
   
  HC; IN
   

 

 

 

 

SCHEDULE 13D

 

item 1. security and issuer

 

This Schedule 13D (this “Statement”) relates to the common stock, par value $0.0001 (the “Shares”), of Genmark Diagnostics, Inc., a company incorporated in Delaware (the “Company”). The principal executive offices of the Company is 5964 La Place Court, Carlsbad, CA, 92008, United States.

 

Item 2. identity and background

 

(a)          The persons filing this Statement are Magnetar Financial LLC, a Delaware limited liability company (“Magnetar Financial”), Magnetar Capital Partners LP, a Delaware limited partnership (“Magnetar Capital Partners”), Supernova Management LLC, a Delaware limited liability company (“Supernova Management”), and Alec N. Litowitz (“Mr. Litowitz”) (collectively, the “Reporting Persons”).

 

This Statement relates to Shares held for the accounts of each of (i)  Magnetar PRA Master Fund Ltd, a Cayman Islands exempted company (“PRA Master Fund”), (ii) Magnetar Constellation Fund II-PRA LP, a Delaware limited partnership (“Constellation Fund”), and (iii) Magnetar Systematic Multi-Strategy Master Fund Ltd, a Cayman Islands exempted company, (“Systematic Master Fund”), collectively (the “Funds”).

 

Magnetar Financial is a Securities and Exchange Commission (“SEC”) registered investment adviser under Section 203 of the Investment Advisers Act of 1940, as amended, and manager of investment funds and managed accounts. Magnetar Financial serves as investment adviser to each of the Funds. In such capacity, Magnetar Financial exercises voting and investment power over the Shares held for the accounts of each of the Funds. Magnetar Capital Partners serves as the sole member and parent holding company of Magnetar Financial. Supernova Management is the general partner of Magnetar Capital Partners. The manager of Supernova Management is Mr. Litowitz.

 

(b)          The business address of each of the Reporting Persons is 1603 Orrington Avenue, 13th Floor, Evanston, Illinois 60201.

 

(c)          Each of the Funds is a private investment fund; Magnetar Financial is a privately-held SEC registered investment adviser and manager of investment funds and managed accounts; Magnetar Capital Partners is a privately-held limited partnership and serves as the sole member and parent holding company of Magnetar Financial; Supernova Management is a privately-held limited liability company and is the general partner of Magnetar Capital Partners; and Mr. Litowitz is a citizen of the United States of America, manager of Supernova Management and Chief Executive Officer of Magnetar Financial.

 

(d)          None of the Reporting Persons has, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

 

(e)          None of the Reporting Persons has, during the last five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction as a result of which such Reporting Person was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

 

 

 

 

(f)           Magnetar Financial is a Delaware limited liability company. Magnetar Capital Partners is a Delaware limited partnership. Supernova Management is a Delaware limited liability company. Mr. Litowitz is a citizen of the United States of America.

 

Item 3. source and amount of funds or other consideration

 

The aggregate amount of funds used by the Reporting Persons in purchasing the 4,221,792 Shares reported herein on behalf of the Funds have come directly from the assets of the Funds, which may at any given time, have included margin loans made by brokerage firms in the ordinary course of business. The aggregate amount of funds used by the Reporting Persons in purchasing the Shares on behalf of the Funds was $100,904,201 (excluding commissions and other execution-related costs).

 

ITEM 4. PURPOSE OF TRANSACTION

 

The Reporting Persons acquired the 4,221,792 Shares reported herein on behalf of the Funds after the public announcement of the Merger Agreement (as defined below) for purposes of receiving the merger consideration described below upon consummation of the Merger (as described below).

 

Each of the Reporting Persons reserves the right to acquire additional securities of the Company in the open market, in privately negotiated transactions, or otherwise, to dispose of all or a portion of the Shares and/or other securities reported in this Statement, or to change their intention with respect to any or all of the matters referred to in this Item 4.

 

Other than as described above in this Item 4, the Reporting Persons do not have any plans or proposals that relate to, or would result in, any actions or events specified in clauses (a) through (j) of Item 4 to Schedule 13D.

 

ITEM 5. INTEREST IN SECURITIES OF THE ISSUER

 

The Company reported in their Form 8-K filed on March 15, 2021 that 73,595,021 Shares were issued and outstanding as of March 11, 2021.

 

(a)          As of the close of business March 24, 2021, each of the Reporting Persons may have been deemed to have beneficial ownership of 4,221,792 Shares, which consisted of (i) 1,716,633 Shares held for the benefit of PRA Master Fund, (ii) 2,072,824 Shares held for the benefit of Constellation Fund; and (iii) 432,335 Shares held for the benefit of Systematic Master Fund, and all such Shares represented beneficial ownership of approximately 5.74% of the Shares.

 

(b)          As of the close of business March 24, 2021, each of the Reporting Persons may have been deemed to share the power to vote and direct the disposition of 4,221,792 Shares, which consisted of (i) 1,716,633 Shares held for the benefit of PRA Master Fund, (ii) 2,072,824 Shares held for the benefit of Constellation Fund; and (iii) 432,335 Shares held for the benefit of Systematic Master Fund, and all such Shares represented beneficial ownership of approximately 5.74% of the Shares.

 

 

 

 

(c)          Except as set forth on Schedule A attached hereto and Item 6, the Funds had no transactions in the Shares during the 60 days preceding the date of filing of this Statement. All of the transactions set forth on Schedule A attached hereto were effected in the ordinary course of business of Magnetar Financial for the accounts of each of the Funds. The transactions in the Shares set forth on Schedule A were effected in open market transactions on NASDAQ and various other trading markets.

 

As disclosed by the Company in the Form 8-K filed with the SEC on March 15, 2021:

 

On March 12, 2021, GenMark Diagnostics, Inc., a Delaware corporation (the “Company”), Roche Holdings, Inc., a Delaware corporation (“Roche”), and Geronimo Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Roche (“Merger Sub”), entered into an Agreement and Plan of Merger (the “Merger Agreement”). Pursuant to the Merger Agreement, and upon the terms and subject to the conditions thereof, Merger Sub will commence a cash tender offer (the “Offer”) to acquire all of the issued and outstanding shares of the common stock, par value $0.0001 per share, of the Company (“Common Stock”) at a price per share of $24.05, net to the seller in cash, without interest (the “Offer Price”), subject to any withholding of taxes required by applicable law. The Offer will initially remain open for 20 business days from the date of commencement of the Offer, subject to extension under certain circumstances.

 

The Merger Agreement provides that, following the consummation of the Offer, Merger Sub will merge with and into the Company (the “Merger”), with the Company surviving the Merger as a wholly owned subsidiary of Roche. The Merger will be governed by Section 251(h) of the General Corporation Law of the State of Delaware, with no stockholder vote required to consummate the Merger. In the Merger, each outstanding share of Common Stock (other than shares of Common Stock held by the Company as treasury stock, or owned by Roche or Merger Sub or held by stockholders who are entitled to demand, and who properly demand, appraisal rights under Delaware law) will be converted into the right to receive cash in an amount equal to the Offer Price, without interest. The Offer and the Merger are not subject to a financing contingency.

 

The Company’s Board of Directors (the “Board”) unanimously determined that the transactions contemplated by the Merger Agreement, including the Offer and the Merger, were advisable and in the best interests of the Company and its stockholders, and unanimously approved the Merger Agreement and the transactions contemplated thereby, and unanimously resolved to recommend, subject to the terms and conditions set forth in the Merger Agreement, that the stockholders of the Company accept the Offer and tender their shares of Common Stock pursuant to the Offer.

 

Immediately prior to the effective time of the Merger (the “Effective Time”), except as provided in the Merger Agreement, each option to purchase Common Stock, whether vested or unvested, outstanding and unexercised immediately prior to the Effective Time will vest (if unvested) and be cancelled and converted into the right to receive (subject to applicable withholding) (i) the excess, if any, of the Offer Price over the per share exercise price of the option, multiplied by (ii) the number of shares of Common Stock issuable upon exercise of such option. Immediately prior to the Effective Time, except as provided in the Merger Agreement, each restricted stock unit of the Company, whether vested or unvested, outstanding immediately prior to the Effective Time will vest (if unvested) and be cancelled and converted into the right to receive the Offer Price (subject to applicable withholding). Immediately prior to the Effective Time, except as provided in the Merger Agreement, each market-based stock unit of the Company, whether vested or unvested, outstanding immediately prior to the Effective Time will vest (based on the performance level attained pursuant to the terms of the applicable award agreement, including provisions relating to the effect of a change of control) and be cancelled and converted into the right to receive the Offer Price (subject to applicable withholding).

 

 

 

 

(d)          No other person is known by the Reporting Persons to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, any Shares that are beneficially owned by the Reporting Persons.

 

Item 6.         contracts, arrangements, understandings or relationships with respect to the securities of the issuer

 

Pursuant to Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the Reporting Persons have entered into an agreement with respect to the joint filing of this Statement, and any amendment or amendments hereto.

 

A client of Magnetar Financial has entered into a total return swap agreement giving it economic exposure to the Company.

 

Certain clients of Magnetar Asset Management LLC (“Magnetar Asset Management”), an SEC registered investment adviser and an affiliate of Magnetar Financial have entered into total return swap agreements giving them economic exposure to the Company. Magnetar Capital Partners serves as the sole member and parent holding company of Magnetar Asset Management.

 

Except as otherwise described herein, no contracts, arrangements, understandings or similar relationships exist with respect to the securities of the Company among or between the Reporting Persons or any other person or entity.

 

 

 

 

ITEM 7. MATERIAL TO BE FILED AS EXHIBITS

 

Exhibit No.   Description
99.1   Joint Filing Agreement, dated as of March 26, 2021 among the Reporting Persons.

 

 

 

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Dated: March 26, 2021

 

  magnetar financial llc
   
  By: Magnetar Capital Partners LP, its Sole Member
   
  By: /s/ Alec N. Litowitz
    Name: Alec N. Litowitz
    Title: Manager of Supernova Management LLC, the General Partner of Magnetar Capital Partners LP
   
  magnetar capital partners LP
   
  By: /s/ Alec N. Litowitz
    Name: Alec N. Litowitz
    Title: Manager of Supernova Management LLC, the General Partner of Magnetar Capital Partners LP
   
  supernova management llc
   
  By: /s/ Alec N. Litowitz
    Name: Alec N. Litowitz
    Title: Manager
   
  /s/ Alec N. Litowitz
  Alec N. Litowitz

 

 

 

 

SCHEDULE A

 

Funds

 

Date   Number of Shares Bought     Price Per Share($) (1)(2)  
3/15/2021     1,247,507       23.89863 (3)
3/16/20201     791,164       23.93658 (4)
3/17/2021     590,117       23.87295 (5)
3/18/2021     642,758       23.86097 (6)
3/19/2021     503,034       23.88495 (7)
3/22/2021     150,310       23.96450 (8)
3/23/2021     163,302       23.97146 (9)
3/24/2021     123,600       23.92755 (10)

 

(1) Excludes commissions and other execution-related costs.

(2) Upon request by the staff of the Securities and Exchange Commission, full information regarding the number of shares bought or sold (as the case may be) at each separate price will be provided.

(3) Reflects a weighted average purchase price of $23.89863 per share, at prices ranging from $23.82 to $23.98 per share.

(4) Reflects a weighted average purchase price of $23.93658 per share, at prices ranging from $23.89 to $23.98 per share.

(5) Reflects a weighted average purchase price of $23.87295 per share, at prices ranging from $23.845 to $23.94 per share.

(6) Reflects a weighted average purchase price of $23.86097 per share, at prices ranging from $23.85 to $23.892 per share.

(7) Reflects a weighted average purchase price of $23.88495 per share, at prices ranging from $23.84 to $23.975 per share.

(8) Reflects a weighted average purchase price of $23.96450 per share, at prices ranging from $23.92 to $23.98 per share.

(9) Reflects a weighted average purchase price of $23.97146 per share, at prices ranging from $23.94 to $23.98 per share.

(10) Reflects a weighted average purchase price of $23.92755 per share, at prices ranging from $23.87 to $23.98 per share.

 

 

 

 

EXHIBIT INDEX

 

Exhibit No.   Description
99.1   Joint Filing Agreement, dated as of March 26, 2021, among the Reporting Persons.

 

 

 

GenMark Diagnostics (NASDAQ:GNMK)
Historical Stock Chart
From Sep 2021 to Oct 2021 Click Here for more GenMark Diagnostics Charts.
GenMark Diagnostics (NASDAQ:GNMK)
Historical Stock Chart
From Oct 2020 to Oct 2021 Click Here for more GenMark Diagnostics Charts.